Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + everolimus
- Development stage
- Phase 3
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Lenvatinib + everolimus** is an oral, two-drug targeted anticancer regimen administered as separate products. Lenvatinib is a multitarget receptor tyrosine kinase inhibitor that blocks VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET, while everolimus is an allosteric mTORC1 inhibitor that acts through FKBP12 binding. The regimen combines antiangiogenic and antiproliferative mTOR-pathway inhibition and is FDA-approved for adults with advanced renal cell carcinoma following one prior antiangiogenic therapy, at lenvatinib 18 mg plus everolimus 5 mg orally once daily. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/lenvatinib-combination-everolimus))
- Other names
- everolimus + lenvatinibLEN + EVElen/evelenvatinib + everolimuslenvatinib and everolimus
02
Targets
FKBP1AKIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)Mechanistic target of rapamycin complex 1FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)
Beyond the preview
Go deeper on lenvatinib + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + everolimus.